Search Page

1

Cite

Share

AID/APOBEC deaminases and cancer.

Rebhandl S, Huemer M, Greil R, Geisberger R. Rebhandl S, et al. Among authors: geisberger r. Oncoscience. 2015 Apr 28;2(4):320-33. doi: 10.18632/oncoscience.155. eCollection 2015. Oncoscience. 2015. PMID: 26097867 Free PMC article. Review.

Cite

Share

2

Cite

Share

Lysine residue at position 22 of the AID protein regulates its class switch activity.

Geisberger R, Huemer M, Gassner FJ, Zaborsky N, Egle A, Greil R. Geisberger R, et al. PLoS One. 2012;7(2):e30667. doi: 10.1371/journal.pone.0030667. Epub 2012 Feb 20. PLoS One. 2012. PMID: 22363466 Free PMC article.

Cite

Share

3

Cite

Share

Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia.

Rebhandl S, Huemer M, Zaborsky N, Gassner FJ, Catakovic K, Felder TK, Greil R, Geisberger R. Rebhandl S, et al. Among authors: geisberger r. Eur J Immunol. 2014 Jul;44(7):2175-87. doi: 10.1002/eji.201343853. Epub 2014 Apr 15. Eur J Immunol. 2014. PMID: 24668151 Free PMC article.

Cite

Share

4

Cite

Share

APOBEC3 signature mutations in chronic lymphocytic leukemia.

Rebhandl S, Huemer M, Gassner FJ, Zaborsky N, Hebenstreit D, Catakovic K, Grössinger EM, Greil R, Geisberger R. Rebhandl S, et al. Among authors: geisberger r. Leukemia. 2014 Sep;28(9):1929-32. doi: 10.1038/leu.2014.160. Epub 2014 May 20. Leukemia. 2014. PMID: 24840555 Free PMC article. No abstract available.

Cite

Share

5

Cite

Share

AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells.

Huemer M, Rebhandl S, Zaborsky N, Gassner FJ, Hainzl S, Weiss L, Hebenstreit D, Greil R, Geisberger R. Huemer M, et al. Among authors: geisberger r. Eur J Immunol. 2014 Dec;44(12):3747-57. doi: 10.1002/eji.201344421. Epub 2014 Oct 18. Eur J Immunol. 2014. PMID: 25179679 Free PMC article. Clinical Trial.

Cite

Share

6

Cite

Share

AIDing cancer treatment: Reducing AID activity via HSP90 inhibition.

Rebhandl S, Geisberger R. Rebhandl S, et al. Among authors: geisberger r. Eur J Immunol. 2015 Aug;45(8):2208-11. doi: 10.1002/eji.201545832. Epub 2015 Jul 7. Eur J Immunol. 2015. PMID: 26151367 Free PMC article.

Cite

Share

7

Cite

Share

The Human NADPH Oxidase, Nox4, Regulates Cytoskeletal Organization in Two Cancer Cell Lines, HepG2 and SH-SY5Y.

Auer S, Rinnerthaler M, Bischof J, Streubel MK, Breitenbach-Koller H, Geisberger R, Aigner E, Cadamuro J, Richter K, Sopjani M, Haschke-Becher E, Felder TK, Breitenbach M. Auer S, et al. Among authors: geisberger r. Front Oncol. 2017 May 31;7:111. doi: 10.3389/fonc.2017.00111. eCollection 2017. Front Oncol. 2017. PMID: 28620580 Free PMC article.

Cite

Share

8

Cite

Share

Imprecision and DNA Break Repair Biased towards Incompatible End Joining in Leukemia.

Gassner FJ, Schubert M, Rebhandl S, Spandl K, Zaborsky N, Catakovic K, Blaimer S, Hebenstreit D, Greil R, Geisberger R. Gassner FJ, et al. Among authors: geisberger r. Mol Cancer Res. 2018 Mar;16(3):428-438. doi: 10.1158/1541-7786.MCR-17-0373. Epub 2017 Dec 8. Mol Cancer Res. 2018. PMID: 29222170 Free PMC article.

Cite

Share

9

Cite

Share

Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.

Zaborsky N, Gassner FJ, Höpner JP, Schubert M, Hebenstreit D, Stark R, Asslaber D, Steiner M, Geisberger R, Greil R, Egle A. Zaborsky N, et al. Among authors: geisberger r. Leukemia. 2019 Apr;33(4):957-968. doi: 10.1038/s41375-018-0260-4. Epub 2018 Sep 27. Leukemia. 2019. PMID: 30262843 Free PMC article.

Cite

Share

10

Cite

Share

Risks and chances of aberrant DNA repair in cancer.

Schubert M, Greil R, Geisberger R. Schubert M, et al. Among authors: geisberger r. Oncoscience. 2018 Aug 22;5(9-10):256-257. doi: 10.18632/oncoscience.459. eCollection 2018 Sep. Oncoscience. 2018. PMID: 30460325 Free PMC article. No abstract available.

Cite

Share